First-in-Human Coronary Intervention Study Results of Robocath's Next-Generation Robotic System Highlighted at TCT

What happened

Stereotaxis announced at the TCT conference results from a 20-patient first-in-human study of Robocath’s next-generation coronary procedure robot. The study reported 100% clinical success, 95% technical success, no device-related adverse events through 30 days, and no physician radiation exposure during procedures.

Confirmed

Global impact / market context

The results could support further use or development of robotic systems for coronary procedures, but a small pilot study does not establish performance in broader patient groups. If adoption grows, robotic procedure demand could affect sales and investment in development or manufacturing, though no commercial impact is reported here.

Analyst inference

The announcement presents early clinical evidence rather than confirmed sales, regulatory clearance, or a launch. For Stereotaxis, investor impact therefore depends on whether further studies and any required approvals translate the reported procedure results into customer demand and revenue; the article gives no financial forecast.

Analyst inference

What to watch

1. Watch for larger or longer studies that test whether the reported success and safety results hold across more patients and different clinical settings. Analyst inference
2. Look for details on regulatory steps or clearances, which are official permissions needed before a medical device can be marketed for specified uses. Analyst inference
3. Track whether Stereotaxis reports product availability, hospital adoption, or sales tied to Robocath’s system; none of these commercial outcomes is stated in the article. Analyst inference

Evidence

• globenewswire.com